Positive News SentimentPositive NewsNASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Price, News & Analysis $1.39 -0.06 (-4.14%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$1.35▼$1.5150-Day Range$1.25▼$6.4652-Week Range$1.04▼$49.80Volume420,253 shsAverage Volume990,092 shsMarket Capitalization$10.24 millionP/E RatioN/ADividend YieldN/APrice Target$70.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Seelos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside4,936.0% Upside$70.00 Price TargetShort InterestBearish9.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector528th out of 950 stocksPharmaceutical Preparations Industry248th out of 442 stocks 3.2 Analyst's Opinion Consensus RatingSeelos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.00, Seelos Therapeutics has a forecasted upside of 4,936.0% from its current price of $1.39.Amount of Analyst CoverageSeelos Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.22% of the float of Seelos Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeelos Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seelos Therapeutics has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEEL. Previous Next 3.3 News and Social Media Coverage News SentimentSeelos Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Seelos Therapeutics this week, compared to 2 articles on an average week.Search Interest28 people have searched for SEEL on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Seelos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.97% of the stock of Seelos Therapeutics is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Seelos Therapeutics Stock (NASDAQ:SEEL)Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Read More SEEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEEL Stock News HeadlinesDecember 22, 2023 | finance.yahoo.comSeelos Therapeutics, Inc. Releases Letter to its StockholdersDecember 20, 2023 | finance.yahoo.com11 Most Promising Psychedelic Stocks According to Hedge FundsDecember 31, 2023 | Behind the Markets (Ad)New Year's Sale: Get 12 Months of Stock Picks for $9.00Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this. December 18, 2023 | msn.comSeelos Therapeutics files for $250M mixed shelfDecember 16, 2023 | msn.comSeelos Therapeutics (SEEL) Price Target Increased by 2900.00% to 122.40December 4, 2023 | finance.yahoo.comInsider Spends US$100k Buying More Shares In Seelos TherapeuticsDecember 2, 2023 | finance.yahoo.comInsider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)December 1, 2023 | finance.yahoo.comSeelos Therapeutics Announces Closing of Public OfferingDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)December 1, 2023 | benzinga.comThinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?November 29, 2023 | benzinga.comThinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?November 29, 2023 | marketwatch.comSeelos Therapeutics Shares Slide Premarket After Public OfferingNovember 29, 2023 | investorplace.comWhy Is Seelos Therapeutics (SEEL) Stock Down 42% Today?November 28, 2023 | markets.businessinsider.comSeelos Therapeutics Announces Pricing Of $5.55 Mln Public Offering; Stock DropsNovember 28, 2023 | msn.comSeelos Therapeutics commences a public offering of its sharesNovember 28, 2023 | finance.yahoo.comSeelos Therapeutics Announces Proposed Public OfferingNovember 28, 2023 | msn.comSeelos stock falls 23% following 1-for-30 reverse splitNovember 28, 2023 | msn.comSeelos Therapeutics, Iterum Therapeutics among healthcare moversNovember 27, 2023 | msn.comDefense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & VeteransNovember 27, 2023 | markets.businessinsider.comSeelos' SLS-002 To Be Included In DOD's Trial To Evaluate Potential Treatments For PTSDNovember 27, 2023 | finance.yahoo.comSeelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)November 24, 2023 | marketwatch.comSeelos to Implement 1-for-30 Reverse Stock SplitNovember 24, 2023 | benzinga.comWhy Seelos Therapeutics Shares Are Diving TodayNovember 24, 2023 | finance.yahoo.comSeelos Therapeutics Announces 1-for-30 Reverse Stock SplitNovember 16, 2023 | msn.comDole (DOLE) Q3 Earnings Top EstimatesNovember 1, 2023 | msn.comSeelos Therapeutics (SEEL) Price Target Increased by 60.00% to 4.08October 27, 2023 | finance.yahoo.comSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023See More Headlines Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees16Year Founded2016Price Target and Rating Average Stock Price Target$70.00 High Stock Price Target$120.00 Low Stock Price Target$30.00 Potential Upside/Downside+4,936.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,530,000.00 Net MarginsN/A Pretax Margin-3,295.87% Return on Equity-10,287.49% Return on Assets-460.15% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.97) per share Price / Book-0.47Miscellaneous Outstanding Shares7,370,000Free Float6,974,000Market Cap$10.24 million OptionableNot Optionable Beta1.82 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Raj Mehra J.D. (Age 63)Ph.D., Founder, Chairman, CEO & President Comp: $854.73kMr. Michael J. Golembiewski (Age 51)Chief Financial Officer Comp: $454.83kMs. Kimberly FarrandSenior Director of Clinical Development & OperationsMr. Anthony MarcianoChief Communications OfficerGopal Krishna Ph.D.Head of Manufacturing & Technical OperationsTim Whitaker M.D.Chief Medical OfficerMs. Karen FusaroSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsJaguar HealthNASDAQ:JAGXBenitec BiopharmaNASDAQ:BNTCAeterna ZentarisNASDAQ:AEZSHillstream BioPharmaNASDAQ:HILSPasithea TherapeuticsNASDAQ:KTTAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 175,078 shares on 12/18/2023Ownership: 96.326%Modera Wealth Management LLCBought 352,271 shares on 11/30/2023Ownership: 22.789%Sabby Management LLCBought 11,792,861 shares on 11/15/2023Ownership: 9.221%Gendell Jeffrey LBought 1,576,565 shares on 11/13/2023Ownership: 5.274%Group One Trading L.P.Sold 1,600 shares on 11/9/2023Ownership: 0.000%View All Institutional Transactions SEEL Stock Analysis - Frequently Asked Questions Should I buy or sell Seelos Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares. View SEEL analyst ratings or view top-rated stocks. What is Seelos Therapeutics' stock price target for 2024? 3 analysts have issued 12 month price targets for Seelos Therapeutics' stock. Their SEEL share price targets range from $30.00 to $120.00. On average, they predict the company's stock price to reach $70.00 in the next twelve months. This suggests a possible upside of 4,936.0% from the stock's current price. View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts. How have SEEL shares performed in 2023? Seelos Therapeutics' stock was trading at $20.37 at the beginning of 2023. Since then, SEEL shares have decreased by 93.2% and is now trading at $1.39. View the best growth stocks for 2023 here. When is Seelos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our SEEL earnings forecast. How were Seelos Therapeutics' earnings last quarter? Seelos Therapeutics, Inc. (NASDAQ:SEEL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($8.41) earnings per share (EPS) for the quarter. The firm earned $0.41 million during the quarter. What ETF holds Seelos Therapeutics' stock ? AdvisorShares Psychedelics ETF holds 312,582 shares of SEEL stock, representing 5.70% of its portfolio. When did Seelos Therapeutics' stock split? Shares of Seelos Therapeutics reverse split on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), OPKO Health (OPK). How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SEEL) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.